Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A2B 395

Next Previous
Search
Drug Profile

A2B 395

Alternative Names: A2B-395; A2B395 Tmod CAR T cells; Allogenic logic-gated Tmod™ CAR T-cell therapy - A2 Biotherapeutics

Latest Information Update: 17 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator A2 Biotherapeutics
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 31 Mar 2025 Phase-I/II clinical trials in Solid tumours (Recurrent, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT06682793)
  • 12 Nov 2024 A2 Biotherapeutics plans the phase I/II DENALI-1 trial for Solid tumours (Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater, Inoperable/Unresectable) in USA (IV), in March 2025 (NCT06682793)
  • 12 Nov 2024 Preclinical trials in Solid tumours in USA (IV), prior to November 2024

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top